©2024 Unity Biotechnology. All Rights Reserved. Terms & Conditions | Privacy Policy
Live
Live
Vibrantly.
Envision
Independence.
UNITY is harnessing pathways of aging biology to develop new medicines, with a focus on retinal diseases.
Transformative Treatments in Ophthalmology
At UNITY we are advancing the first senolytic therapeutic for retinal diseases.
Lead senolytic candidate UBX1325 has a novel mechanism of action that potentially provides longer lasting improvements in vision compared to current standard of care for diabetic macular edema.
Pioneers in Cellular Senescence
Cellular senescence is the underlying biology behind many chronic and inflammatory diseases that take a tremendous toll on our health and quality of life as we age.
UNITY is at the forefront of developing a new class of therapeutics that aim to restore diseased tissue to a healthier state.
Phase 2 Study Results in DME
Positive clinical data from the Phase 2 BEHOLD study in DME demonstrates a single injection of UBX1325 led to a sustained statistically significant and clinically meaningful improvement in vision.
ASPIRE Study Enrollment Complete
The Phase 2b ASPIRE Study is designed to evaluate UBX1325 in comparison to aflibercept in previously treated patients with active DME who are not achieving optimal benefit from standard of care.